NCT07063043 Clinical Research on 68Ga-FAPI PET/CMR in Cardiovascular Diseases
| NCT ID | NCT07063043 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Shanghai East Hospital |
| Condition | Cardiovascular Diseases (CVD) |
| Study Type | OBSERVATIONAL |
| Enrollment | 40 participants |
| Start Date | 2024-12-01 |
| Primary Completion | 2028-12-31 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 40 participants in total. It began in 2024-12-01 with a primary completion date of 2028-12-31.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
FAP-targeted PET imaging using 68Ga-FAPI enables early detection of myocardial fibrosis. Combined PET/CMR provides comprehensive cardiac assessment without extra radiation. This advanced imaging approach improves diagnosis and personalized treatment for better patient outcomes.
Eligibility Criteria
Inclusion Criteria: * Participants must have a confirmed clinical diagnosis of cardiovascular disease by a cardiologist, based on genetic testing, family history, and comprehensive clinical evaluation including physical examination, echocardiography, and when indicated, cardiac MRI findings. * Age requirement: \>18 years. * Patients should demonstrate stable cardiovascular status without significant changes in symptoms, treatment, or clinical findings for a specified pre-enrollment period. * Participants must be capable of providing informed consent and willing to adhere to all study requirements, including follow-up procedures. Exclusion Criteria: * History of malignancy * Documented cardiovascular diseases, including coronary artery disease, myocardial infarction, or related conditions * Implanted metallic devices (e.g., pacemakers, aneurysm clips) or other MRI-incompatible medical prostheses * Claustrophobia * Pregnancy or lactation * Known hypersensitivity to gadolinium-based contrast agents * Renal impairment (eGFR \<30 mL/min/1.73m² by CKD-EPI equation)
Contact & Investigator
Frequently Asked Questions
Who can join the NCT07063043 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Cardiovascular Diseases (CVD). Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07063043 currently recruiting?
Yes, NCT07063043 is actively recruiting participants. Contact the research team at dingjie940406@163.com for enrollment information.
Where is the NCT07063043 trial being conducted?
This trial is being conducted at Shanghai, China.
Who is sponsoring the NCT07063043 clinical trial?
NCT07063043 is sponsored by Shanghai East Hospital. The trial plans to enroll 40 participants.